LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LB-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LB-100 overview
LB-100 is under development for the treatment of soft tissue sarcoma, recurrent glioblastoma multiforme, del5q myelodysplastic syndrome, advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor), small cell lung cancer ovarian clear cell carcinoma, peritoneal cancer and fallopian tube cancer. It is a synthetic derivative of cantharidin. The drug candidate is administered through intravenous route and oral route. It acts by targeting protein phosphatase 2A (PP2A).
It was also under development for the treatment of solid tumors including colon cancer, pancreatic cancer, breast cancer, carcinoid tumor, testicular cancer, duodenal cancer, non-small cell lung cancer, thymoma, hepatocellular carcinoma (HCC), pheochromocytoma, sarcoma, melanoma, insulin resistance, acute ischemia of brain, septic shock, depression, myocardial ischemia, post-traumatic stress disorder (PTSD),type 2 diabetes, Angelman syndrome, triple negative breast cancer, metastatic colorectal cancer, achondroplasia and obesity.
Lixte Biotechnology overview
Lixte Biotechnology (Lixte) is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of a new class of cancer therapies through its novel Protein Phosphatase 2A (PP2A) inhibitors. The company’s product pipeline centers on developing inhibitors of protein phosphatase 2A. These inhibitors are designed to work alongside chemotherapy, radiation, immune checkpoint blockers, and other cancer treatments. Its lead product candidate, LB-100, is a small molecule that inhibits PP2A, demonstrating significant anti-cancer activity with minimal toxicity. The company is also developing the LB-200 series focusing on histone deacetylase inhibitors (HDACi). Lixte is headquartered in Pasadena, California, the US.
For a complete picture of LB-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
